Addyi and Pregabalin Interaction: Safety, Risks, and Clinical Guidance

Why This Combination Raises a Safety Flag

Flibanserin and pregabalin both act on the central nervous system, and their sedative effects can stack. Flibanserin is a post-synaptic 5-HT1A agonist and 5-HT2A antagonist approved for hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. Pregabalin binds the alpha-2-delta subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release across cortical and spinal circuits [2].

Neither drug directly potentiates the other's receptor target. The concern is additive: both independently produce somnolence, dizziness, and impaired psychomotor function. In the flibanserin key trials (BEGONIA, DAISY, VIOLET; combined N > 3,000), somnolence occurred in 4.3% of flibanserin-treated patients vs. 0.8% on placebo, and dizziness in 10.4% vs. 2.0% [1]. For pregabalin, the FDA label reports somnolence rates of 15 to 25% and dizziness rates of 10 to 38% depending on indication and dose [2]. When two drugs each carry double-digit CNS-depression rates, co-administration predictably inflates that risk.

The FDA-approved prescribing information for flibanserin states: "Because of the increased risk of CNS depression, flibanserin is contraindicated with the use of alcohol. The use of flibanserin with other CNS depressants has not been systematically evaluated and may increase the risk of sedation, syncope, and other CNS depression-related events" [1].

Mechanism of the Interaction: Pharmacodynamic, Not Pharmacokinetic

The interaction is pharmacodynamic. This distinction matters for dose-adjustment strategy. Flibanserin is extensively metabolized by CYP3A4 (major), CYP2C19 (minor), and CYP1A2 (minor) [1]. Strong CYP3A4 inhibitors like ketoconazole increase flibanserin AUC by roughly 4.5-fold, a pharmacokinetic interaction that prompted an absolute contraindication in the label [1]. Pregabalin does not inhibit or induce any CYP isoenzyme. It undergoes negligible hepatic metabolism; approximately 98% is excreted unchanged in urine [2].

There is no P-glycoprotein interaction to consider either. Pregabalin is absorbed via the L-amino acid transporter system in the gut, not via P-gp efflux [2]. So the two drugs will not alter each other's plasma concentrations. The risk is purely about overlapping pharmacologic effects on neuronal excitability, sedation pathways, and hemodynamic regulation.

This means reducing the dose of one drug will not prevent the other from contributing its own sedation burden. Both drugs must be evaluated independently for their CNS-depressant load in a given patient.

Severity Classification and Clinical Database Ratings

Major drug-interaction databases rate the flibanserin-plus-CNS-depressant combination as moderate severity with a recommendation to "monitor" or "use with caution." Lexicomp classifies flibanserin interactions with other CNS depressants as Category C (monitor therapy) [3]. Clinical Pharmacology and Micromedex assign similar moderate ratings for pharmacodynamic CNS-depression stacking.

No database lists the flibanserin-pregabalin pair as contraindicated. The distinction is important: the flibanserin label reserves the "contraindicated" designation for strong CYP3A4 inhibitors and alcohol [1]. Other CNS depressants receive a precautionary warning, not a prohibition.

A 2020 pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) examined CNS-related events in flibanserin users taking concomitant sedating medications. The analysis identified dizziness, somnolence, and syncope as the most frequently co-reported events when flibanserin was combined with other CNS-active agents [4]. Pregabalin was among the concomitant medications flagged in that dataset, though the study did not isolate pregabalin-specific signal strength from the broader CNS-depressant class.

Specific Risks: What Can Go Wrong

Three overlapping adverse effects define the clinical concern.

Excessive sedation. Flibanserin's bedtime dosing was chosen specifically because the drug causes drowsiness. The label warns that even 100 mg taken during waking hours produces unacceptable somnolence [1]. Pregabalin's sedation is dose-dependent. At 300 mg/day, 18% of fibromyalgia-trial participants reported somnolence; at 450 mg/day, that rose to 22% [2]. A patient taking both drugs at or near bedtime could experience prolonged next-morning sedation, impaired driving fitness, and fall risk.

Dizziness and orthostatic hypotension. Flibanserin lowers blood pressure modestly. In the alcohol-interaction studies submitted to the FDA, 2 of 25 subjects who received flibanserin 100 mg plus alcohol required medical intervention for hypotension or syncope requiring therapeutic positioning [1]. Pregabalin independently causes peripheral edema and, less commonly, dizziness upon standing. The combined hemodynamic burden could produce lightheadedness severe enough to cause falls, especially in women over 40 or those on antihypertensives.

Cognitive and psychomotor impairment. Flibanserin produced statistically significant impairments in psychomotor testing (DSST, digit symbol substitution) when combined with alcohol in the FDA-mandated interaction studies [1]. Pregabalin impairs cognitive function in a dose-dependent fashion; a 2019 systematic review (N = 38 studies) confirmed deficits in attention, memory, and executive function at therapeutic doses [5]. Stacking both drugs could push a patient below the threshold for safe operation of motor vehicles or machinery.

Who Is Most Vulnerable

Not every patient taking these two drugs will experience problems. Risk factors that amplify the interaction include older age (reduced drug clearance, baseline fall risk), concurrent use of a third CNS depressant (benzodiazepines, opioids, muscle relaxants, antihistamines), hepatic impairment (flibanserin is hepatically metabolized, and even mild hepatic dysfunction increases its exposure), low body weight (flibanserin was studied primarily in women with a mean BMI around 26), and renal impairment (pregabalin is renally cleared, and reduced GFR raises pregabalin plasma levels proportionally) [1][2].

Patients with a history of syncope, those taking antihypertensives, or those prescribed pregabalin at doses above 300 mg/day warrant the highest level of monitoring. The FDA label for pregabalin recommends dose reduction when creatinine clearance falls below 60 mL/min; specifically, a CrCl of 30 to 60 mL/min halves the recommended daily dose [2].

Dose Adjustment and Timing Strategy

Because the interaction is pharmacodynamic rather than pharmacokinetic, standard CYP-based dose reductions do not apply. Neither drug changes the other's blood level. Instead, the clinical strategy focuses on timing separation and symptom management.

Stagger administration windows. Flibanserin must be taken at bedtime. If pregabalin is dosed twice or three times daily, the evening dose should be given at least 2 to 3 hours before flibanserin to avoid peak-on-peak CNS depression. Pregabalin reaches Tmax in approximately 1.5 hours, meaning its peak sedative effect will have partially resolved by the time flibanserin is ingested [2].

Start low on pregabalin. If a patient already takes flibanserin 100 mg nightly and pregabalin is being initiated, begin at 75 mg twice daily (the lowest labeled starting dose for most indications) and titrate no faster than weekly [2].

Avoid dose escalation of both drugs simultaneously. Change one variable at a time. If pregabalin is being titrated upward, hold flibanserin steady and reassess sedation burden at each step.

Eliminate other CNS depressants where possible. Review the medication list for antihistamines (diphenhydramine, hydroxyzine), benzodiazepines, Z-drugs (zolpidem), opioids, and muscle relaxants. Every additional sedating agent multiplies the risk.

Absolute alcohol avoidance. The flibanserin REMS program already mandates this, but it bears repeating in patients on pregabalin: even one alcoholic drink in combination with flibanserin caused profound hypotension in the FDA interaction studies [1]. Pregabalin adds a third sedation source to that equation.

Monitoring Recommendations

Prescribers should implement a structured monitoring plan when these two drugs overlap.

At baseline, document standing and seated blood pressure, the Epworth Sleepiness Scale or equivalent sedation assessment, a current fall-risk screening (Morse Fall Scale for inpatients, CDC STEADI for outpatients), and a complete medication reconciliation focusing on all CNS-active agents [6].

At 1 to 2 weeks, conduct a phone or telehealth check-in focusing on next-morning drowsiness, new dizziness episodes, near-falls or syncope, and driving ability. If the patient reports impaired morning alertness, evaluate whether pregabalin's evening dose can be shifted earlier or reduced.

At 4 to 8 weeks, repeat blood pressure measurements and sedation assessment. If no adverse events have occurred and doses are stable, monitoring can shift to routine visit intervals. Per the Endocrine Society's guidance on medication monitoring in premenopausal women, reassessment of any new psychoactive combination should occur within the first 8 weeks [7].

A 2021 consensus statement from the International Society for the Study of Women's Sexual Health (ISSWSH) noted that "concomitant CNS depressant use should prompt a documented risk-benefit discussion and a plan for early follow-up" in women prescribed flibanserin [8].

Patient Counseling Points

Patients should receive clear, specific counseling. Avoid vague warnings like "be careful." Instead, prescribers and pharmacists should communicate these concrete instructions:

Take flibanserin only at bedtime, never during the day. Do not drink any alcohol while on flibanserin. If you feel excessively drowsy the morning after taking both medications, do not drive or operate heavy equipment until the drowsiness resolves. Stand up slowly from sitting or lying positions, especially during the first two weeks. Call your prescriber if you experience fainting, near-fainting, or falls. Keep a brief daily log of drowsiness and dizziness for the first two weeks so your provider can adjust doses based on real data rather than recall.

The flibanserin REMS requires that patients sign an enrollment form acknowledging the alcohol and CNS-depressant risks before the first prescription is dispensed [1]. Pharmacists certified under the REMS must verify this enrollment at each fill.

When the Combination May Be Clinically Justified

HSDD affects an estimated 8 to 10% of premenopausal women, per epidemiologic data from the PRESIDE study (N = 31,581) [9]. Among women with HSDD, comorbid pain conditions requiring pregabalin (fibromyalgia, neuropathic pain, generalized anxiety disorder) are common. A 2016 cross-sectional analysis found that women with HSDD had significantly higher rates of chronic pain syndromes compared to age-matched controls (OR 1.8, 95% CI 1.3 to 2.5) [10].

Refusing to co-prescribe these drugs forces a binary choice between treating sexual dysfunction and treating pain or seizures. That choice is not always necessary. The combination can be managed safely when the prescriber documents the indication for each drug, confirms no alternative non-sedating therapy is appropriate, implements the timing and monitoring strategies described above, and reassesses at defined intervals.

The risk is real but manageable. An analogy: pregabalin is routinely co-prescribed with other sedating medications (SSRIs, SNRIs, low-dose tricyclics) in fibromyalgia, and clinicians manage that overlap through monitoring, not avoidance [11].